Study guide
3.1 Drug Classifications, Interactions, and Cross-Tolerance
IC&RC Alcohol and Drug Counselor ADC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Applying, Scoring, and Retakes
2 Domain I: Addiction Science
2.1 Neurobiology of Addiction 2.2 Risk Factors for Substance Use Disorders 2.3 Stages and Patterns of Substance Use Disorders
3 Domain I: Pharmacology Foundations
3.1 Drug Classifications, Interactions, and Cross-Tolerance 3.2 Intoxication and Overdose 3.3 Withdrawal Syndromes
4 Domain I: Major Substances
4.1 Alcohol 4.2 Sedative-Hypnotics and Benzodiazepines 4.3 Stimulants 4.4 Opioids
5 Domain I: Other Substances and Co-Occurring Conditions
5.1 Cannabis, Hallucinogens, Dissociatives, Inhalants, and Nicotine 5.2 Physiological, Psychological, and Social Effects 5.3 Co-Occurring Mental Health Conditions 5.4 Co-Occurring Medical Conditions
6 Domain II: Screening and Interviewing
6.1 Assessment Interviewing Techniques 6.2 Motivational Interviewing in Screening and Assessment 6.3 Brief Screening Instruments 6.4 Comprehensive Assessment Instruments
7 Domain II: Diagnosis and History
7.1 Drug and Alcohol Testing 7.2 DSM-5-TR Substance Use Disorder Criteria 7.3 Specifiers, Severity, and Differential Diagnosis 7.4 Biopsychosocial History and Collateral Sources
8 Domain II: Needs and Placement
8.1 Immediate and Ongoing Needs 8.2 ASAM Assessment Dimensions 8.3 ASAM Levels of Care and Placement
9 Domain III: Communication, Rapport, and Crisis
9.1 Communication and Learning Styles 9.2 Building Rapport 9.3 Reviewing Patterns and Methods of Use 9.4 Crisis Response and De-escalation
10 Domain III: Case Management and Populations
10.1 Referrals, Case Management, and Resources 10.2 Youth and Pregnancy 10.3 LGBTQ+, Justice-Involved, and Housing-Insecure Clients 10.4 Multidisciplinary Collaboration and Family Supports
11 Domain III: Trauma, Change, and Treatment Planning
11.1 Trauma and the Client 11.2 Vicarious Trauma and Counselor Burnout 11.3 Ambivalence, Resistance, and Feedback 11.4 Treatment Planning
12 Domain III: Groups, Discharge, and Recovery Pathways
12.1 Group Curriculum and Process 12.2 Group Dynamics and Cohesiveness 12.3 Discharge Planning and Termination 12.4 Multiple Pathways of Recovery including MAT
13 Domain IV: Boundaries and Scope
13.1 Dual Relationships 13.2 Self-Disclosure and Self-Awareness 13.3 Scope of Practice 13.4 Conflicts of Interest
14 Domain IV: Culture, Equity, and Rights
14.1 Multicultural Perspectives 14.2 Diversity, Inclusion, and Equity in Care 14.3 Client and Patient Rights
15 Domain IV: Documentation and Privacy
15.1 Documentation and Record Storage 15.2 42 CFR Part 2 Confidentiality 15.3 HIPAA and Privacy Intersections
16 Domain IV: Consent, Supervision, and Grievances
16.1 Informed Consent 16.2 Supervision and Consultation 16.3 Client Grievances
3.1 Drug Classifications, Interactions, and Cross-Tolerance
Key Takeaways Explain This Topic AI
ADC Domain I is 25% of the exam; task I.D.1 covers pharmacology, including drug classifications, interactions, and cross-tolerance (ADC Candidate Guide, effective November 2022, checked 2026-09-20).
Alcohol and benzodiazepines share GABA-A cross-tolerance; that pairing is the classic fact, not alcohol with cannabis, amphetamines, or opioids as a GABA mechanism.
Pharmacodynamic synergy (alcohol plus benzodiazepines or opioids) multiplies CNS depression; pharmacokinetic interactions change absorption, distribution, metabolism, or excretion (for example CYP2E1 and acetaminophen).
At the mu receptor, methadone, heroin, and fentanyl are full agonists, buprenorphine is a partial agonist with a ceiling, naloxone is the short-acting overdose antagonist, and naltrexone is a longer-acting planned-blockade antagonist.
This section is independent ADC study material by ExamFinch and does not claim IC&RC approval, partnership, or exact equivalence with IC&RC training.
Last updated: September 2026
Why pharmacology belongs on the ADC exam
The IC&RC Alcohol and Drug Counselor (ADC) Examination weights Domain I: Scientific Principles of Substance Use and Co-Occurring Disorders at 25% of scored content. Task I.D.1 in the ADC Candidate Guide (effective November 2022; PDF posted July 2025 at https://internationalcredentialing.org/wp-content/uploads/2025/07/ADC-Candidate-Guide-2022.pdf , checked 2026-09-20 ) asks candidates to differentiate common substances by pharmacology , including drug classifications , interactions , and cross-tolerance . This section is independent ADC study material by ExamFinch . ExamFinch does not claim IC&RC approval, partnership, or exact equivalence with IC&RC courseware. Official item writing, scoring, and candidate rules remain IC&RC and member-board products.
You will not be scored on writing a prescription. You will be scored on whether you can explain why a fifth-a-day drinker may look only mildly sedated after a benzodiazepine dose that would drop a naive adult, why alcohol plus an opioid is not two harmless nightcaps, and why naloxone reverses an opioid overdose but does nothing to a pure alcohol coma.
At Northbridge Recovery Center , counselor Dana Ellis completes intake with Marcus , age 42. He drinks roughly a fifth of vodka most days, swallows alprazolam borrowed from a cousin to take the edge off, and for ten days has taken leftover oxycodone after a dental extraction. He reports that none of it does much anymore. Domain I.D.1 is the vocabulary Dana needs before she ever writes a treatment plan.
Clinical classification: uppers, downers, and all-arounders
Many counselor texts sort psychoactive drugs into uppers (central nervous system, or CNS , stimulants), downers (CNS depressants), and all-arounders (drugs that distort perception—cannabis, classic hallucinogens, and many dissociatives). That map is useful on the unit. The exam also expects pharmacologic class : the receptor or transporter the drug primarily hits. Class predicts intoxication, overdose, withdrawal, and which combinations stack.
Class Prototype agents Primary target Intoxication snapshot
CNS depressants (alcohol and sedative-hypnotics) Ethanol, diazepam, alprazolam, phenobarbital, zolpidem, gamma-hydroxybutyrate ( GHB ) Enhance gamma-aminobutyric acid type A ( GABA-A ) inhibition; alcohol also dampens excitatory glutamate / N-methyl-D-aspartate ( NMDA ) signaling Sedation, slurred speech, ataxia, slowed thinking
Stimulants Cocaine, methamphetamine, amphetamine salts, nicotine, caffeine Raise synaptic dopamine and norepinephrine (and often serotonin ) Euphoria, tachycardia, dilated pupils, less sleep and appetite
Opioids Heroin, fentanyl, oxycodone, morphine, methadone, buprenorphine Mu , kappa , and delta opioid receptors Analgesia, euphoria, pinpoint pupils, constipation, slowed breathing
Cannabinoids Delta-9-tetrahydrocannabinol ( THC )-dominant cannabis; some synthetics Cannabinoid type 1 ( CB1 ) and type 2 ( CB2 ) receptors Relaxation, altered time sense, increased appetite, red conjunctiva
Classic hallucinogens Lysergic acid diethylamide ( LSD ), psilocybin, mescaline Serotonin 2A ( 5-HT2A ) receptor agonism Perceptual change, labile affect, orientation often preserved
Dissociatives (often grouped with hallucinogens) Phencyclidine ( PCP ), ketamine, high-dose dextromethorphan NMDA glutamate antagonism Detachment, nystagmus, unpredictable agitation
Trap: treating every downer as the same pharmacology. Alcohol, benzodiazepines, and barbiturates move GABA-A in the same direction. Opioids also depress the CNS, but they act at opioid receptors, not as GABA-A positive modulators. That split decides cross-tolerance items here and which withdrawal can kill in section 3.3.
Receptor actions: agonist, partial agonist, antagonist
A receptor is a protein a drug binds. The action is what happens next.
A full agonist binds and produces a near-maximal effect. At the mu receptor that includes heroin, fentanyl, morphine, oxycodone, and methadone .
A partial agonist binds and produces a ceiling lower than a full agonist. Buprenorphine is a high-affinity partial mu agonist and a kappa antagonist. The ceiling is why respiratory depression plateaus relative to fentanyl at high dose. High affinity is why buprenorphine can precipitate withdrawal if it knocks a full agonist off mu receptors while that agonist is still on board.
An antagonist occupies the receptor and blocks agonists without turning the receptor on. Naloxone is a short-acting competitive mu antagonist used to reverse opioid overdose. Naltrexone is a longer-acting antagonist used in planned relapse-prevention pathways (oral or extended-release), not as the usual field rescue spray.
Worked Northbridge example: Marcus still has oxycodone in his system. A roommate gives him a large first strip of buprenorphine to help him stop. Within minutes he is yawning, sweating, vomiting, and covered in gooseflesh. That is precipitated opioid withdrawal —receptor occupancy—not an allergy.
Trap: calling naltrexone the street-rescue antagonist. Community kits are naloxone (intranasal or injectable). Naltrexone also occupies mu receptors and can precipitate withdrawal, but counseling uses it as planned blockade after an opioid-free window. Another trap: calling buprenorphine a full opioid interchangeable with methadone. Both appear in medication-for-addiction-treatment discussions later in this guide; the receptor math is not the same.
Pharmacokinetic versus pharmacodynamic interactions
An interaction is any change in effect when two substances are present.
Pharmacokinetic ( PK ) interactions change how much drug reaches the target : absorption , distribution , metabolism , or excretion (often remembered as ADME ). Examples Dana uses in psychoeducation:
Chronic heavy alcohol use induces cytochrome P450 2E1 ( CYP2E1 ), which can increase conversion of acetaminophen to a hepatotoxic metabolite—relevant when Marcus lives on extra-strength acetaminophen for hangovers.
Several benzodiazepines (including alprazolam) and many opioids are CYP3A4 substrates. Strong inhibitors can raise blood levels; inducers can drop them.
Cirrhosis, aging, and first-pass metabolism change levels without changing the receptor itself.
Pharmacodynamic ( PD ) interactions change what the drugs do together at tissues , even if each concentration is unchanged. Alcohol plus a benzodiazepine is the ADC prototype: both increase GABA-A inhibitory tone. The result is synergistic CNS depression —combined impairment and overdose risk greater than one drink plus one pill. Alcohol plus an opioid stacks two depressant systems (GABA/glutamate disruption plus mu-mediated reduction of respiratory drive). Benzodiazepine–opioid pairs carry the same PD warning: additive and synergistic respiratory depression.
Marcus's triad—vodka, alprazolam, oxycodone—is a PD emergency in slow motion, not a clever self-taper. Dana names the combination, teaches without shaming, and coordinates with medical staff. She does not tell him to just skip the benzo tonight as if that were a monitored detox plan.
Interaction type What changes Northbridge example Exam cue words
Pharmacokinetic Blood level or clearance Acetaminophen plus chronic alcohol raises liver-injury risk CYP, half-life, levels went up
Pharmacodynamic Receptor or system effect Alcohol plus alprazolam produces synergistic sedation Same class, same vital-sign direction, synergy
Mixed Both level and effect Cirrhosis raising benzo levels and alcohol still on GABA-A Do not pick only one if the stem gives both
Cross-tolerance: alcohol and benzodiazepines
Tolerance means a larger dose is required for the same effect, or the same dose produces less effect. Cross-tolerance means tolerance to drug A reduces response to drug B because they share a mechanism.
The pairing ADC candidates must not miss is cross-tolerance between alcohol and benzodiazepines . Both facilitate GABA-A receptor function. A brain adapted to daily ethanol is also adapted to benzodiazepines. That is why:
Marcus may swallow several alprazolam tablets and still look only buzzed.
Alcohol-withdrawal protocols often use benzodiazepines: they can substitute at GABA-A and blunt autonomic hyperactivity and seizures ( cross-dependence ).
A client who never takes pills but drinks a handle weekly is not benzodiazepine-naive in GABA terms.
Cross-tolerance also runs among benzodiazepines, barbiturates, and other sedative-hypnotics that hit GABA-A. It does not classically pair alcohol with cannabis (CB1), amphetamines (monoamine releasers or reuptake blockers), or opioids (mu receptors) as the textbook GABA example. Opioids and alcohol both depress the CNS and can kill together; that is synergistic PD depression , not the same fact as GABA-A cross-tolerance.
Reverse tolerance (sensitization), described with some stimulant patterns, is the opposite direction: less drug, more effect. Do not drop that term into an alcohol–benzo stem.
Dana's family-night sentence: alcohol and benzodiazepines press the same brain brake. Using both is two feet on one pedal. Over time the pedal gets harder to push. When you stop, the brain can slam into overdrive.
Classification and interaction traps
Equating opioid downers with alcohol and benzodiazepine GABA-A pharmacology.
Naming cannabis, amphetamines, or opioids as alcohol's cross-tolerance partner on a GABA item.
Calling buprenorphine a full mu agonist, or calling naloxone the long-acting relapse-prevention antagonist (that role is naltrexone).
Labeling alcohol plus a benzodiazepine as only pharmacokinetic because the liver processes both.
Assuming a client who denies pill problems cannot have benzodiazepine cross-tolerance if they drink daily.
Treating independent ExamFinch practice as an IC&RC-published exam form.